SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (861)12/4/1998 2:25:00 PM
From: Douglas Babbin  Read Replies (2) | Respond to of 965
 
Some how I don't think CNTO sold off do to Retavase and Crohns disease. I believe it began instead with the allergic reaction patients had when switching from an older Remicade formulation to the new powder formulation for those with Rheumatoid Arthritis. Correct me if I'm wrong.